Revenue Update on Neurometrix Inc(NASDAQ:NURO)

Neurometrix Inc(NASDAQ:NURO) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 21, 2016. Company reported revenue of $2.65M. Analysts estimated a revenue of $2.28M. Earnings per share were $-0.92.

In a different note, Rodman & Renshaw said it Initiates Coverage on Neurometrix Inc, according to a research note issued on Jun 28, 2016. The shares have been rated ‘Buy’ by the firm.

Neurometrix Inc (NURO) made into the market gainers list on Wednesdays trading session with the shares advancing 1.16% or 0.02 points. Due to strong positive momentum, the stock ended at $1.74, which is also near the day’s high of $1.75. The stock began the session at $1.75 and the volume stood at 27,867 shares. The 52-week high of the shares is $4.96 and the 52 week low is $1.35. The company has a current market capitalization of $7.6 M and it has 43,89,899 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 1, 2016, Shai Gozani (CEO) purchased 2,500 shares at $1.71 per share price.Also, On May 23, 2016, Francis X Mcgillin (Senior VP, Consumer) purchased 1,000 shares at $1.65 per share price.On May 19, 2016, Thomas T Higgins (CFO) purchased 3,200 shares at $1.54 per share price, according to the Form-4 filing with the securities and exchange commission.

NeuroMetrix Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain nerve diseases and sleep disorders. The Company is engaged in product development manufacturing regulatory affairs and compliance sales and marketing and customer support. The Company sells medical devices and after-market consumable products and accessories. The Company has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. The Company’s products include Quell SENSUS DPNCheck and ADVANCE System.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Neurometrix Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Neurometrix Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.